RxDoctor Payments Data

Susan Ross, MD

Family Medicine · Chestertown, MDNPI 1417950080

Payments from drug & device makers

$241in general payments, 2019–2025

Across 9 payments — averaging $26.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$125
  • EMD Serono, Inc.$58
  • GSK$29
  • Merck$17
  • Novo Nordisk$11

What the payments were for

  • Food & beverage$241100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen1$125
EMD Serono, Inc.4$58
GSK2$29
Merck1$17
Novo Nordisk1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$241 in reported general payments places this provider in the 45th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$199,244
Medicare patients
417
Services billed
2,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$141,737
OzempicSemaglutide45$57,427
XareltoRivaroxaban65$47,997
MounjaroTirzepatide41$42,994
JanuviaSitagliptin Phosphate39$37,500
TrulicityDulaglutide16$19,418
JardianceEmpagliflozin17$18,996
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,403
OxycontinOxycodone Hcl12$12,062
MyrbetriqMirabegron23$10,292
Breo ElliptaFluticasone/Vilanterol17$9,453
Potassium Chloride288$8,120
Metoprolol Succinate308$6,007
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$5,685
Rosuvastatin Calcium244$4,589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$11$57,42745 claims
MerckJanuvia$17$37,50039 claims
GSKTrelegy Ellipta, Breo Ellipta$29$22,85636 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Chestertown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →